from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»

News

SEMINAIRE JEUDI 02 MAI 14H

Noboru MIZUSHIMATokyo University (Japan)"intracellular degradation and quality control by autophagy"host: Sophie Pattingre (IRCM)Autophagy is an intracellular degradation system conserved in many eukaryotes. In the process of autophagy, a portion of the cytoplasm is surrounded by autophagosomes and then delivered to lysosomes for degradation. Studies on the molecular mechanism and physiological function of autophagy have made remarkable progress over the past 20 years since the landmark genetic studies in yeast by Dr. Ohsumi and other groups. In this seminar, I will summarize the current status of autophagy research, including methodology, and discuss some recent topics on autophagosome-lysosome fusion, selective degradation of mitochondria by autophagy, and the reversibility of cellular dysfunction caused by autophagy defects.   
En savoir plus

SEMINAIRE JEUDI 02 MAI 14H (copie)

Noboru MIZUSHIMATokyo University (Japan)"intracellular degradation and quality control by autophagy"host: Sophie Pattingre (IRCM)Autophagy is an intracellular degradation system conserved in many eukaryotes. In the process of autophagy, a portion of the cytoplasm is surrounded by autophagosomes and then delivered to lysosomes for degradation. Studies on the molecular mechanism and physiological function of autophagy have made remarkable progress over the past 20 years since the landmark genetic studies in yeast by Dr. Ohsumi and other groups. In this seminar, I will summarize the current status of autophagy research, including methodology, and discuss some recent topics on autophagosome-lysosome fusion, selective degradation of mitochondria by autophagy, and the reversibility of cellular dysfunction caused by autophagy defects.   
En savoir plus

SEMINAIRE VENDREDI 03 MAI 14h

Thomas DAUBONInstitut de Biochimie et Génétique Cellulaires, UMR 5095 CNRS Université de Bordeaux"The PacMan effect : when glioblastoma cells eat myelin to invade the brain"host : Julie Pannequin (IGF) / Laurent Le Cam (IRCM)
En savoir plus

SEMINAIRE VENDREDI 03 MAI 14h (copie)

Thomas DAUBONInstitut de Biochimie et Génétique Cellulaires, UMR 5095 CNRS Université de Bordeaux "The PacMan effect : when glioblastoma cells eat myelin to invade the brain"host : Julie Pannequin (IGF) / Laurent Le Cam (IRCM)
En savoir plus

SEMINAIRE VENDREDI 17 MAI 14h

Arnaud BLOMMELaboratory of Metabolic Regulation, GIGA-Research Institute, University of Liège, Belgique"Targeting mTORC2-dependent metabolic vulnerabilities in lung cancer"hôte: Andrei Turtoi (IRCM-Inserm)
En savoir plus

SEMINAIRE VENDREDI 17 MAI 14h (copie)

Arnaud BLOMMELaboratory of Metabolic Regulation, GIGA-Research Institute, University of Liège, Belgique "Targeting mTORC2-dependent metabolic vulnerabilities in lung cancer"hôte: Andrei Turtoi (IRCM-Inserm)
En savoir plus

Postdoctoral Position in cell matrix biology & antibody-drug conjugate (IRCM, INSERM U1194, Montpellier, France)

Publié le 22/02/24Application deadline: 31 Mars 2024Anticipated start date: ASAP 2024The team (Breast cancer, Microenvironment and Immunotargeting) at Montpellier Cancer ResearchInstitute (France) is looking for a postdoctoral researcher to work on the optimization of antibodydrugconjugates targeting matricellular proteins in breast cancer. This postdoctoral fellowship is partof a priority research program and equipment (PEPR) ACCREDIA, which brings together a lab networkof seven academic partners funded by the French government to improve knowledge, skills andmethodologies in antibody development. The position is funded in the frame of French PEPR-PIA4Accredia ANR-22-PEBI-0009 for a period of 2 to 3 years.  More
En savoir plus

SEMINAIRE IRCM VENDREDI 26 AVRIL

Thierry DUBOISInstitut Curie – Centre de Recherche, Département Recherche Translationnelle & CNRS UMR144  Groupe « Biologie du Cancer du Sein »“Protein arginine methyltransferases (PRMTs) in triple-negative breast cancer: potential targets and functional studies”host : Eric JULIEN (IRCM) 
En savoir plus

SEMINAIRE IRCM VENDREDI 26 AVRIL (copie)

Thierry DUBOISInstitut Curie – Centre de Recherche, Département Recherche Translationnelle & CNRS UMR144   Groupe « Biologie du Cancer du Sein »“Protein arginine methyltransferases (PRMTs) in triple-negative breast cancer: potential targets and functional studies”host : Eric JULIEN (IRCM) 
En savoir plus

Andrei Turtoi team is recruiting a PhD Student within the framework of ACINETWORK, a european project funded through Horizon Europe Marie Sk?odowska-Curie Doctoral Network programme. Deadline : 31st January 2024

Publié le 080124Andrei Turtoi team is recruiting a PhD Student within the framework of ACINETWORK, a european project funded through Horizon Europe Marie Sk?odowska-Curie Doctoral Network programme.  Deadline : 31st January 2024For more information and application please visit https://acinetwork.eu/
En savoir plus

the word of the director

"Together, let's push the limits."

"In barely 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has succeeded in raising its research to the highest international level in the field of fundamental and applied cancer research, carried out in close collaboration with the clinical departments of the Montpellier Cancer Center (ICM: l'Institut du Cancer de Montpellier), and industrial partners. Under the joint supervision of Inserm, the ICM and the University of Montpellier, the IRCM brings together more than 240 people, researchers, clinicians, technicians and students, organized in 16 research teams that rely on high-performance technical platforms and competent support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead. To do so, we will continue to structure cancer research in Montpellier, to seek excellence and to accelerate innovation and transfer to the patient in order to ultimately contribute to overcoming the countless different forms of cancer. Together, let's push the limits"

Nathalie Bonnefoy, Director of the IRCM

the word of the director

MAIN PUBLICATIONS

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

Brustel J, Kirstein N, Izard F, Grimaud C, Prorok P, Cayrou C, Schotta G, Abdelsamie A, Déjardin J, Méchali M, Baldacci G, Sardet C, Cadoret J-C, Schepers A, Julien E Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication. EMBO J.. 2017;36(18):2726-2741. doi:10.15252/embj.201796541


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés